Beta Bionics Management
Management criteria checks 1/4
Beta Bionics' CEO is Sean Saint, appointed in Aug 2022, has a tenure of 3.75 years. total yearly compensation is $12.19M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.98% of the company’s shares, worth $4.12M. The average tenure of the management team and the board of directors is 3.5 years and 1.6 years respectively.
Key information
Sean Saint
Chief executive officer
US$12.2m
Total compensation
| CEO salary percentage | 5.74% |
| CEO tenure | 3.8yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.5yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Beta Bionics: Speculative Appeal After An Eventful Start To The Year
Summary Beta Bionics shares have plunged over two-thirds since December, driven by disappointing 2026 guidance and slowing momentum. BBNX's 2026 revenue guidance of $130–$135 million signals minimal growth from Q4’s annualized $128 million, raising concerns about sustained operational losses. Despite $265 million in net cash, BBNX trades at just over 1x sales, reflecting deep investor skepticism and speculative appeal after severe multiple compression. FDA warnings and competitive risks further pressure sentiment, but current valuation appears de-risked, offering speculative upside if growth reaccelerates. Read the full article on Seeking AlphaBeta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
The Beta Bionics, Inc. ( NASDAQ:BBNX ) share price has fared very poorly over the last month, falling by a substantial...
Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook
Catalysts About Beta Bionics Beta Bionics develops automated insulin delivery systems aimed at simplifying diabetes management for people using insulin pumps. What are the underlying business or industry changes driving this perspective?We're Hopeful That Beta Bionics (NASDAQ:BBNX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Beta Bionics, Inc. (NASDAQ:BBNX) Looks Just Right With A 35% Price Jump
Despite an already strong run, Beta Bionics, Inc. ( NASDAQ:BBNX ) shares have been powering on, with a gain of 35% in...Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Beta Bionics: Slowing Down Or Being Conservative?
Summary Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure. With substantial net cash holdings, the stock remains interesting if the guidance is conservative, offering potential upside given the current low valuation. Read the full article on Seeking AlphaBeta Bionics: A Sugar Rush For This IPO
Summary Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company’s iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years. While the growth is compelling, risks include competition, reliance on partners, and the single-product nature, making me cautious about initiating a position now. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$66m |
| Dec 31 2025 | US$12m | US$700k | -US$73m |
| Sep 30 2025 | n/a | n/a | -US$78m |
| Jun 30 2025 | n/a | n/a | -US$73m |
| Mar 31 2025 | n/a | n/a | -US$71m |
| Dec 31 2024 | US$886k | US$492k | -US$55m |
Compensation vs Market: Sean's total compensation ($USD12.19M) is above average for companies of similar size in the US market ($USD2.72M).
Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.
CEO
Sean Saint (49 yo)
Mr. Sean T. Saint, PE serves as Director at Beta Bionics, Inc. from August, 2022 and serves as its President. He serves as Chief Executive Officer at Beta Bionics, Inc. from August, 15 2022. He is an engin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.8yrs | US$12.19m | 0.98% $ 4.1m | |
| CFO, Treasurer & Secretary | 3.8yrs | US$5.20m | 0.39% $ 1.6m | |
| Chief Product Officer | 2.8yrs | US$3.64m | 0.42% $ 1.8m | |
| Vice President of Operations | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Medical Officer | 3.5yrs | no data | 0.40% $ 1.7m | |
| Chief Commercial Officer | 2.6yrs | US$992.43k | 0.31% $ 1.3m |
Experienced Management: BBNX's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.8yrs | US$12.19m | 0.98% $ 4.1m | |
| Independent Director | 6.3yrs | US$225.00k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$204.67k | no data | |
| Independent Director | 1.6yrs | US$242.50k | no data | |
| Independent Director | 1.3yrs | US$232.50k | 0.028% $ 117.1k | |
| Independent Director | 1.3yrs | US$232.50k | 0% $ 0 | |
| Independent Chairperson | 2.4yrs | US$287.50k | 0.028% $ 117.1k |
Experienced Board: BBNX's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 10:07 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beta Bionics, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |